Romidepsin | Celgene | ||
10 mg/vial; Powder, Intravenous |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
None | ||
Less Than 5
|
Less Than 5
|
||
second-line treatment for cutaneous T-cell lymphoma, or CTCL. | |||
Yes
|
Istodax | Patent 1 | Patent 2 |
---|---|---|
********** | ******* | ******* |
**** | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
********** | *** \ ** | *** **, **** | ******* | **** | ******** ** *** **, **** ** ** |
**** | ** \ ** | *** **, **** | ******* | **** | ******** ** *** **, **** ** ** |